The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

The FDA has approved oral brensocatib (Brinsupri) for adults and children 12+ with non-cystic fibrosis bronchiectasis. As a ...

Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with ...

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...

Insmed has received FDA clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be ...

Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

The Food and Drug Administration (FDA) has approved Brinsupri ™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older.

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis ...